Chimeric orthopoxvirus

Author: wgsx

August undefined, 2024

WebApr 28, 2024 · One hundred chimeric orthopoxvirus plaques were picked from CV-1 cells infected with the chimeric orthopoxvirus pool. These 100 plaques were further plaque purified two more times in CV-1 cells to … WebCF33-hNIS, a novel chimeric orthopoxvirus, will be administered as a monotherapy or in combination with pembrolizumab to assess the safety and efficacy of the treatment …

Neural Stem Cells Improve the Delivery of Oncolytic Chimeric ...

WebBackground: CF33-hNIS-anti-PD-L1 is a novel chimeric orthopoxvirus shown to have anti-cancer activity in triple negative breast cancer (TNBC) xenografts. For clinical tracking of the oncolytic ... WebNov 4, 2024 · Description: This licence authorises Medpace Australia Pty Ltd to conduct a clinical trial of a genetically modified (GM) chimeric orthopoxvirus as a cancer treatment in Australia. The genetically modified organism (GMO) is genetically similar to the vaccinia virus used as a vaccine during the global smallpox eradication campaign. csub spring 2022

Novel Chimeric Immuno-Oncolytic Virus CF33-hNIS-antiPDL1 …

WebJul 6, 2024 · Neural Stem Cells Improve the Delivery of Oncolytic Chimeric Orthopoxvirus in a Metastatic Ovarian Cancer Model Mol Ther Oncolytics. 2024 Jul 6;18:326-334. doi: 10.1016/j ... that this NSC line can improve the delivery of a thymidine kinase gene-deficient conditionally replication-competent orthopoxvirus, CF33, in a … WebOrthopoxvirus is a genus of viruses in the family Poxviridae and subfamily Chordopoxvirinae.Vertebrates, including mammals and humans, and arthropods serve as natural hosts. There are 12 species in this genus. … WebJun 29, 2024 · One hundred chimeric orthopoxvirus plaques were picked from CV-1 cells infected with the chimeric orthopoxvirus pool. These 100 plaques were further plaque purified two more times in CV-1 cells to yield 100 clonally purified individual chimeric virus isolates, which, together with the parental viruses, were subjected to high-throughput ... early rectal prolapse in dogs

Novel Chimeric Immuno-Oncolytic Virus CF33-hNIS-antiPDL1 for ... - LWW

WebNational Center for Biotechnology Information csub spss downloadWebJun 6, 2024 · CF33-hNIS Infects, Replicates in, and Kills Colon Cancer Cells. Chimerization and high-throughput analysis yielded a successful chimeric orthopoxvirus candidate that resulted in superior cell killing and viral replication when compared with parental strains, as previously reported.14, 15, 16 Insertion of hNIS at the tk locus (Figure 1 A) resulted in … early rectal cancer symptoms

"WebCF33-hNIS-antiPDL1 is a genetically engineered chimeric orthopoxvirus, CF33, armed with the human Sodium Iodide Symporter (hNIS) and anti-PD-L1 antibody (anti-PD-L1). The in vitro cytotoxic ability of this virus against 5 PDAC cell lines was tested at various doses (multiplicity of infection [MOI] = 0.01, 0.1, 1, 10). " - Chimeric orthopoxvirus

Chimeric orthopoxvirus

Endogenous Akt Activity Promotes Virus Entry and …

WebFor these studies, we used an oncolytic chimeric orthopoxvirus, designed to infect a large spectrum of tumors (13) (14)(15)(16)(17), carrying CD19t under the control of the vaccinia synthetic ... WebJun 29, 2024 · Chimeric Orthopoxvirus CF33 Effectively Kills TNBC In Vitro CF33 demonstrates both time- and dose-dependent cytotoxicity against four different TNBC …

Did you know?

WebApr 1, 2024 · Study Design. CF33-hNIS-antiPDL1 is a genetically engineered chimeric orthopoxvirus, CF33, armed with the human Sodium Iodide Symporter (hNIS) and anti-PD-L1 antibody (anti-PD-L1). The in vitro cytotoxic ability of this virus against 5 PDAC cell lines was tested at various doses (multiplicity of infection [MOI] = 0.01, 0.1, 1, 10). WebFor these studies, we used an oncolytic chimeric orthopoxvirus, de-signed to infect a large spectrum of tumors (13–17), carrying CD19t under the control of the vaccinia synthetic early promoter (P SE; Fig. 1A). This construction enables rapid expression of CD19t and appearance of the protein at the cell surface before oncolytic viral-

WebApr 28, 2024 · Chimeric Orthopoxvirus CF33 Effectively Kills TNBC In Vitro CF33 demonstrates both time- and dose-dependent cytotoxicity against four different TNBC cell lines. In the BT549, Hs578T, and MDA … WebCF33-hNIS-antiPDL1 is a genetically engineered chimeric orthopoxvirus, CF33, armed with the human Sodium Iodide Symporter (hNIS) and anti-PD-L1 antibody (anti-PD-L1). …

WebFeb 1, 2024 · CF33-hNIS-antiPDL1, a chimeric orthopoxvirus expressing the human sodium iodide symporter (hNIS) and anti-human programmed death-ligand 1 antibody, has demonstrated robust preclinical activity ... WebSep 25, 2024 · One such OV is CF33, a chimeric poxvirus created by chimerization of nine species of orthopoxvirus, including multiple strains of vaccinia virus selected for enhanced anti-tumor activity. 23, 24, 25 CF33 has a mutation in the J2R (thymidine kinase [TK]) gene, and hence it depends on the cellular pool of thymidine triphosphate.

WebStudy design: CF33-hNIS-antiPDL1 is a genetically engineered chimeric orthopoxvirus, CF33, armed with the human Sodium Iodide Symporter (hNIS) and anti-PD-L1 antibody …

Orthopoxvirus is a genus of viruses in the family Poxviridae and subfamily Chordopoxvirinae. Vertebrates, including mammals and humans, and arthropods serve as natural hosts. There are 12 species in this genus. Diseases associated with this genus include smallpox, cowpox, horsepox, camelpox, and monkeypox. The most widely known member of the genus is Variola virus, which causes smallpox. It was eradicated globally by 1977, through the use of Vaccinia virus as a vac… early rectal prolapseWebAug 15, 2024 · Introduction and Objective: CF33-hNIS is a novel, chimeric orthopoxvirus with robust anti-tumor activity at relatively low titers and with a low multiple of infectivity (MOI) in a variety of pre-clinical models. This is a Phase 1, open-label, dose escalation study in adult patients with selected advanced or metastatic solid tumors to evaluate the safety … earlyredWebApr 26, 2024 · Novel chimeric orthopoxvirus isolates CF33 and CF17 show superior cancer cell killing capability compared to the parental individual wild-type virus strains. Fifty-four solid cancer cell lines in ... csub spring 2022 classesWebJun 17, 2024 · A novel oncolytic chimeric orthopoxvirus encoding luciferase enables real-time view of colorectal cancer cell infection. Mol Ther Oncolytics. 2024;9:13–21. PubMed PubMed Central Google Scholar csub spring scheduleWebOct 9, 2024 · The conditionally replication-competent chimeric orthopoxvirus (CF17) successfully exhibited the ability to suppress tumor growth and increase survival in preclinical peritoneal ovarian metastases … early recurrent ischemic strokeWebJun 2, 2024 · CF33-hNIS-anti-PD-L1 (CHECKvacc) is a novel chimeric orthopoxvirus with robust anti-cancer activity in TNBC xenografts. Cells infected with CHECKvacc were shown to express functional human sodium-iodide symporter (hNIS) and anti-PD-L1 proteins. hNIS gene transfer allows tracking of virus by 99mTc single-photon emission computed … csub software downloadsWebScientific Abstract: Oncolytic virotherapy represents a promising approach for treating recurrent and/or drug-resistant ovarian cancer. However, its successful application in the … csub spss